Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study

Simple item page
dc.contributor.authorSekaggya-Wiltshire, Christine
dc.contributor.authorCastelnuovo, Barbara
dc.contributor.authorBraun, Amrei von
dc.contributor.authorMusaazi, Joseph
dc.contributor.authorMuller, Daniel
dc.contributor.authorBuzibye, Allan
dc.contributor.authorGutteck, Ursula
dc.contributor.authorHenning, Lars
dc.contributor.authorLedergerber, Bruno
dc.contributor.authorCorti, Natascia
dc.contributor.authorLamorde, Mohammed
dc.contributor.authorFehr, Jan
dc.contributor.authorKambugu, Andrew
dc.date.accessioned2023-03-03T17:17:12Z
dc.date.available2023-03-03T17:17:12Z
dc.date.issued2017
dc.description.abstractTuberculosis (TB) is a leading cause of death among people living with HIV in sub-Saharan Africa. Several factors influence the efficacy of TB treatment by leading to suboptimal drug concentrations and subsequently affecting treatment outcome. The aim of this cohort is to determine the association between anti-TB drug concentrations and TB treatment outcomes. Participants Patients diagnosed with new pulmonary TB at the integrated TB-HIV outpatient clinic in Kampala, Uganda, were enrolled into the study and started on firstline anti-TB treatment. Findings to date Between April 2013 and April 2015, the cohort enrolled 268 patients coinfected with TB/HIV ; 57.8% are male with a median age of 34 years (IQR 29–40). The median time between the diagnosis of HIV and the diagnosis of TB is 2 months (IQR 0–22.5). The majority of the patients are antiretroviral therapy naive (75.4%). Our population is severely immunosuppressed with a median CD4 cell count at enrolment of 163 cells/μL (IQR 46–298). Ninety-nine per cent of the patients had a diagnosis of pulmonary TB confirmed by sputum microscopy, Xpert/RIF or culture and 203 (75.7%) have completed TB treatment with 5099 aliquots of blood collected for pharmacokinetic analysis. Future plans This cohort provides a large database of well-characterised patients coinfected with TB/HIV which will facilitate the description of the association between serum drug concentrations and TB treatment outcomes as well as provide a research platform for future substudies including evaluation of virological outcomes.en_US
dc.identifier.citationSekaggya-Wiltshire C, Castelnuovo B, von Braun A, et al. Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study. BMJ Open 2017;7:e014679. doi:10.1136/ bmjopen-2016-014679en_US
dc.identifier.other10.1136/ bmjopen-2016-014679
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/8064
dc.language.isoenen_US
dc.publisherBMJ openen_US
dc.subjectCohort profileen_US
dc.subjectTuberculosisen_US
dc.subjectAntiretroviral drug concentrationsen_US
dc.subjectDesignen_US
dc.titleCohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH studyen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Cohort profile of a study on outcomes.pdf
Size:
591.99 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences